Lisinopril and Trazodone Interaction: Safety, Risks, and Monitoring

Why This Combination Gets Flagged

Lisinopril and trazodone each lower blood pressure through different mechanisms, and their effects stack. That additive hypotensive potential is the reason drug-interaction checkers flag this pair as a moderate-severity interaction. The concern is not a metabolic conflict. Neither drug meaningfully alters the other's plasma concentration. The problem is pharmacodynamic: two agents pushing blood pressure downward at the same time.

Lisinopril, an ACE inhibitor, blocks the conversion of angiotensin I to angiotensin II, reducing both vasoconstriction and aldosterone secretion. The FDA-approved label for lisinopril lists hypotension as a recognized adverse effect, especially in volume-depleted patients or those on concurrent antihypertensives [1]. Trazodone, classified as a serotonin antagonist and reuptake inhibitor (SARI), was developed as an antidepressant but is now prescribed far more often at low doses for insomnia. Its alpha-1 adrenergic blockade produces vasodilation that is separate from its serotonergic activity [2]. A 2019 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) confirmed that trazodone-associated hypotension reports were disproportionately elevated compared to other antidepressants in the SARI and SSRI classes (pubmed.ncbi.nlm.nih.gov/30746899) [3].

The interaction is not rare in practice. Lisinopril was dispensed over 88 million times in 2022 according to ClinCalc Drug Usage Statistics, making it the most commonly prescribed antihypertensive in the United States. Trazodone ranks among the top 25 most dispensed medications overall. Overlap is inevitable.

Mechanism of the Interaction

The interaction between lisinopril and trazodone is pharmacodynamic, not pharmacokinetic. This distinction matters for clinical management.

Lisinopril is not metabolized by the liver. It is absorbed as the active drug, circulates without hepatic transformation, and is excreted renally unchanged (pubmed.ncbi.nlm.nih.gov/3527872) [4]. There is no CYP450 involvement. Trazodone, by contrast, is extensively metabolized by CYP3A4 to its active metabolite meta-chlorophenylpiperazine (mCPP) [2]. Because lisinopril does not inhibit or induce any CYP isoenzyme, it will not alter trazodone's clearance, peak concentration, or half-life.

The risk sits entirely in overlapping hemodynamic effects. Lisinopril reduces systemic vascular resistance by suppressing angiotensin II. Trazodone reduces vascular tone through direct alpha-1 receptor blockade, a mechanism shared with prazosin and other alpha-blockers. When a patient stands up, the normal compensatory vasoconstriction mediated by alpha-1 receptors is blunted by trazodone at the same time that the renin-angiotensin buffer is suppressed by lisinopril. The result can be a measurable orthostatic blood-pressure drop.

A clinical review published in the Journal of Clinical Psychopharmacology noted that trazodone-induced orthostatic hypotension occurred in approximately 5 to 7% of patients at standard antidepressant doses (150 to 300 mg/day), with the incidence rising in patients already taking antihypertensives (pubmed.ncbi.nlm.nih.gov/6094370) [5]. The lower doses used for insomnia (25 to 100 mg) carry a proportionally smaller but nonzero risk.

Clinical Severity and Database Ratings

Drug-interaction databases classify the lisinopril-trazodone pair as moderate severity, meaning clinicians should monitor and may need to adjust timing or dose, but the combination is not contraindicated. This is a management-level interaction, not an avoidance-level one.

Lexicomp rates the interaction as "Monitor Therapy." Clinical Pharmacology (Elsevier) assigns it a severity rating of "moderate" with a documentation level of "fair." Neither database recommends automatic discontinuation. The American Heart Association's 2017 hypertension guideline acknowledges that concurrent medications with hypotensive properties should prompt more frequent blood-pressure assessment but does not single out trazodone specifically (pubmed.ncbi.nlm.nih.gov/29133356) [6].

For context, the same "moderate" label applies to the combination of lisinopril with most other antidepressants that carry alpha-blocking or vasodilatory properties, including mirtazapine and low-potency tricyclics like amitriptyline.

Who Is at Higher Risk

Not every patient taking both medications will experience problems. Risk concentrates in specific populations, and recognizing them allows targeted monitoring rather than blanket avoidance.

Older adults face the highest risk. Age-related baroreflex impairment reduces the body's ability to compensate for blood-pressure drops upon standing. A prospective cohort study in the Journal of the American Geriatrics Society (N=765) found that patients aged 65 and older taking an antihypertensive plus a sedating psychotropic had a 2.1-fold increased odds ratio for falls compared with those on the antihypertensive alone (pubmed.ncbi.nlm.nih.gov/9588706) [7]. Falls in this group carry serious consequences: hip fracture, subdural hematoma, and prolonged hospitalization.

Volume-depleted patients are also vulnerable. Lisinopril's label explicitly warns that patients on diuretics, those with sodium restriction, or those with diarrhea or vomiting may experience exaggerated first-dose hypotension [1]. Adding trazodone in that setting compounds the deficit. Patients with heart failure (NYHA Class III or IV) already operate with reduced cardiac output and limited hemodynamic reserve, making even a small additional blood-pressure reduction clinically meaningful.

Other higher-risk groups include patients with autonomic neuropathy (common in long-standing diabetes), patients taking other alpha-blocking agents such as tamsulosin for BPH, and patients who are early in their lisinopril titration and have not yet reached hemodynamic steady state.

Monitoring Protocol

Structured monitoring prevents the interaction from becoming a clinical event. The goal is simple: catch orthostatic hypotension before it causes a fall or syncope.

At baseline, measure blood pressure in both the seated and standing positions before starting trazodone. A drop of 20 mmHg systolic or 10 mmHg diastolic within three minutes of standing defines orthostatic hypotension per the American Academy of Neurology consensus statement (pubmed.ncbi.nlm.nih.gov/8602759) [8]. If orthostatic hypotension already exists at baseline, the risk from adding trazodone is higher, and the starting dose should be minimized.

During the first two weeks, patients should check standing blood pressure at home or return to clinic for a repeat orthostatic assessment. Most trazodone-induced hypotension manifests within the first 7 to 14 days, because the alpha-1 blockade effect is maximal early and partial tolerance may develop over weeks [5]. After one month on a stable dose of both drugs, routine monitoring can return to standard intervals for the underlying hypertension management.

Patients should be counseled to rise slowly from seated or supine positions, particularly during the first week. Nighttime bathroom trips are a high-risk window because trazodone is typically dosed at bedtime. Adequate hydration, avoiding alcohol (which adds a third hypotensive layer), and reporting dizziness or lightheadedness early are all practical safeguards.

Dose-Adjustment Strategies

When initiating trazodone in a patient already stable on lisinopril, a "start low, go slow" approach minimizes hypotensive risk. The FDA label for trazodone recommends an initial dose of 150 mg/day in divided doses for depression, but clinicians prescribing for insomnia commonly begin at 25 to 50 mg at bedtime [2].

For patients on moderate or high-dose lisinopril (20 to 40 mg), starting trazodone at 25 mg is reasonable. If the insomnia indication requires escalation, increase by no more than 25 mg every 5 to 7 days. For patients being titrated on both drugs simultaneously (less common but seen in new-diagnosis hypertension with concurrent insomnia), stagger the introduction by at least one week so that the hemodynamic contribution of each drug can be assessed independently.

If symptomatic orthostatic hypotension occurs, the first step is timing adjustment: move the lisinopril dose to the morning and keep trazodone at bedtime. This separates the peak plasma concentrations by approximately 12 hours. Lisinopril reaches peak plasma concentration at roughly 7 hours post-dose, while trazodone peaks at 1 to 2 hours [1][2]. If timing alone is insufficient, a lisinopril dose reduction of 5 to 10 mg may be warranted, guided by blood-pressure targets.

Dr. William White, a hypertension researcher at the University of Connecticut, has noted in published commentary that "ambulatory blood pressure monitoring is underused when assessing drug-drug hemodynamic interactions; office readings miss the nocturnal dip that a bedtime alpha-blocker like trazodone amplifies" (pubmed.ncbi.nlm.nih.gov/11775139) [9].

What About Hyperkalemia and Serotonin Syndrome?

Two other interaction concerns sometimes appear in patient forums but do not apply to this specific pair.

Hyperkalemia is a real risk with lisinopril. ACE inhibitors reduce aldosterone, which in turn reduces renal potassium excretion. The interaction that matters is lisinopril plus potassium-sparing diuretics, potassium supplements, or NSAIDs. Trazodone does not affect potassium handling. No mechanism exists for trazodone to worsen lisinopril-associated hyperkalemia, and no case reports have been published linking the two drugs to elevated potassium [1][2].

Serotonin syndrome requires the combination of two serotonergic agents. Lisinopril has zero serotonergic activity. It does not inhibit serotonin reuptake, activate serotonin receptors, or inhibit monoamine oxidase. The serotonin syndrome concern with trazodone arises when it is combined with SSRIs, SNRIs, MAOIs, tramadol, or other serotonergic drugs. Lisinopril is not in that category. A review of serotonin syndrome in the New England Journal of Medicine confirmed that the condition requires at least one serotonin-enhancing drug at each end of the synapse or receptor (pubmed.ncbi.nlm.nih.gov/15784664) [10]. ACE inhibitors are absent from every published serotonin syndrome precipitant list.

When to Contact Your Prescriber

Specific symptoms should prompt a same-day call to the prescribing physician. Dizziness lasting more than a few seconds upon standing, near-syncope (graying of vision, sensation of almost passing out), actual syncope, or a measured standing systolic blood pressure below 90 mmHg all require reassessment. Heart rate increases of more than 20 beats per minute from sitting to standing may indicate compensatory tachycardia secondary to hypotension, even if the patient does not feel overtly dizzy.

The 2023 Beers Criteria from the American Geriatrics Society recommends caution with combinations of antihypertensives and CNS-active medications in adults aged 65 and older, specifically because of fall risk (pubmed.ncbi.nlm.nih.gov/36550925) [11]. For older patients experiencing recurrent dizziness, the prescriber may consider switching from trazodone to a non-alpha-blocking sleep agent such as low-dose melatonin or suvorexant, or reducing the lisinopril dose if blood-pressure targets allow it.

Dr. Joseph Saseen, Professor of Clinical Pharmacy at the University of Colorado, has stated in clinical guidance materials that "the reflex among clinicians to simply add a sleep aid to an existing antihypertensive regimen without rechecking orthostatic vitals misses a preventable cause of falls in the ambulatory setting" (pubmed.ncbi.nlm.nih.gov/29133356) [6].

Patients stable on both drugs for more than four weeks with no orthostatic symptoms can continue the combination with standard blood-pressure follow-up every 3 to 6 months.